Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech’s disclosures can feel like a full-time job. Structure Therapeutics’ reports are packed with GPCR science, clinical trial nuances and dilution math that few investors have time to untangle. That’s why this page offers Structure Therapeutics SEC filings explained simply—so you can move past technical jargon and focus on the signals that matter.
Stock Titan’s AI reads every new document the moment it hits EDGAR and produces clear summaries you can trust. Need the Structure Therapeutics quarterly earnings report 10-Q filing translated into plain English? Wondering which risk factors changed in the latest 10-K? Our engine highlights R&D burn, cash runway and trial milestones in a click. You’ll also find real-time alerts for Structure Therapeutics Form 4 insider transactions real-time, giving you immediate insight into executive conviction. Looking for strategic shifts? The platform tags each Structure Therapeutics 8-K material events explained entry so you can understand partnership news or study results without combing through pages.
Use the table below to scan every form, from the Structure Therapeutics annual report 10-K simplified to the Structure Therapeutics proxy statement executive compensation. Track Structure Therapeutics insider trading Form 4 transactions, compare segments across quarters, and explore Structure Therapeutics earnings report filing analysis before making your next move. Whether you’re monitoring Structure Therapeutics executive stock transactions Form 4 or simply understanding Structure Therapeutics SEC documents with AI, our platform delivers all filings—plus AI-powered commentary—so you spend less time reading and more time deciding.
Structure Therapeutics (GPCR) Director Russell Angus C. received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 42,833 share options with the following key terms:
- Exercise price: $7.37 per share, based on fair market value of Ordinary Shares
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
- Each ADS (American Depositary Share) represents 3 Ordinary Shares
This equity compensation grant aligns with standard director compensation practices and demonstrates long-term commitment to the company. The 10-year exercise window provides significant time value for the options.
Structure Therapeutics (GPCR) director Ted W. Love received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 51,804 share options with the following key terms:
- Exercise price: $7.37 per share, based on ADS trading price
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
The options convert to ordinary shares, with each ADS representing three ordinary shares. This grant aligns the director's interests with shareholders through long-term equity compensation. The transaction was reported via Form 4 filing within the required timeframe, with signature by attorney-in-fact Jun Yoon on June 25, 2025.
Structure Therapeutics (GPCR) Director Joanne Waldstreicher received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 51,804 share options with the following key terms:
- Exercise price: $7.37 per share, based on ADS trading price
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
- Each ADS represents 3 ordinary shares
This equity compensation grant aligns the director's interests with shareholders and provides long-term incentive through a 10-year exercise window. The vesting schedule ensures continued engagement through the next annual meeting cycle.
Structure Therapeutics Inc. (GPCR) – Form 4 insider filing
Director Eric Dobmeier reported the grant of 51,804 share options on 23 June 2025. The options carry an exercise price of $7.37 per ordinary share, equal to the fair-market value on the grant date. Vesting occurs in equal monthly instalments over twelve months beginning 23 June 2025; any unvested portion will become fully vested immediately prior to the company’s 2026 annual shareholder meeting. The options expire on 22 June 2035.
Following this grant, Mr. Dobmeier beneficially owns 51,804 derivative securities and no changes to his non-derivative share holdings were disclosed. Ownership is reported as direct. Each American Depositary Share represents three ordinary shares, but the filing reports the transaction in ordinary-share terms.
No open-market purchases, sales, or other equity transactions were reported. The filing therefore represents a routine board compensation event rather than a market transaction and is unlikely to have a material impact on near-term share price.
Structure Therapeutics (GPCR) reported a Form 4 filing disclosing insider trading activity by Director Sharon Tetlow on June 23, 2025. The transaction involved the acquisition of derivative securities in the form of stock options.
Key transaction details:
- Acquired 51,804 stock options to purchase ordinary shares
- Exercise price set at $7.37 per share, based on ADS trading price
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting accelerates to immediately prior to 2026 annual shareholder meeting
Each American Depositary Share (ADS) represents three ordinary shares of the company. The options were granted at fair market value based on the ADS trading price at the time of grant.
Structure Therapeutics (GPCR) Director Daniel G. Welch received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 51,804 share options to purchase ordinary shares at an exercise price of $7.37 per share.
Key details of the option grant:
- Exercise price is based on the fair market value of ordinary shares on grant date
- Options vest monthly over 12 months from June 23, 2025
- Full vesting accelerates before the 2026 annual shareholder meeting
- Options expire on June 22, 2035
- Each ADS (American Depositary Share) represents 3 ordinary shares
This equity compensation grant aligns with standard director compensation practices and demonstrates continued commitment to the company's long-term growth.
FAQ
What is the current stock price of Structure Therapeutics ADR (GPCR)?
What is the market cap of Structure Therapeutics ADR (GPCR)?
What is the core focus of Structure Therapeutics Inc?
How does the company differentiate its therapies from traditional treatments?
Which therapeutic targets does Structure Therapeutics concentrate on?
What approach does Structure Therapeutics use in its drug discovery process?
Why are oral small molecules significant in the treatment landscape?
How does the company ensure its clinical-stage products address unmet medical needs?
What are the key benefits of the company’s structure-based drug discovery platform?
How is Structure Therapeutics positioned within its competitive landscape?
